- Product portfolio to include drugs and supplements
- Faster monetization of lead Alzheimer’s candidate as supplement
- Market valuation poised to soar
It should come as no surprise to discover that the medical cannabis dispensary product line in America is getting increasingly diverse and sophisticated. After all, the cannabis sativa plant incorporates over 400 chemical entities, of which more than 60 are cannabinoids. Even though cannabis has been used and cultivated by mankind for at least 6,000 years, it was only relatively recently, in 1899, that the first cannabinoid, cannabinol (CBN), was identified and isolated. With so much chemistry wrapped in its trichomes, colas and bracts, the range of ailments for which the plant promises palliatives continues to grow. Based on compelling data, India Globalization Capital, Inc. (NYSE MKT: IGC) was recently able to announce advances in the treatment of Alzheimer’s disease with THC. These encouraging results have brightened the company’s future, since the market for Alzheimer’s therapies is a billion-dollar one.
The IGC press release (http://cnw.fm/ryAm0) provided an update on in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model, showing that, at varying concentrations of THC, the aggregation of Aβ protein decreases by as much as 40%. There are indications that at least one cause of AD may be the buildup of senile plaque composed of amyloid beta peptides (Aβ plaque) in the cerebral cortex and hippocampus. Over time, this plaque destroys neurons and causes synaptic dysfunction, leading to loss of memory.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer